AI in Medicine News — 2026-10-31 (Sat) Daily News

Overview

Diagnostic imaging news centered on a study of an AI agent reading emergency abdominal ultrasounds (99.6% diagnostic accuracy) and an FDA clearance for AI-powered bone visualization software (Bioengineer.org, BioBuzz). Regulation and governance were the most active area, covering FDA oversight of generative AI devices, state-level clinical AI testing, a California law, and a European roadmap (Modern Healthcare, STAT, Hunton Andrews Kurth LLP, EMJ). In drug development, an AI-designed compound received FDA clearance for Phase 1/2 in advanced solid tumours, and Anthropic acquired a biotech startup (Dealroom, European Pharmaceutical Review).

Diagnostics and imaging

- An AI agent read emergency abdominal ultrasounds with 99.6% diagnostic accuracy in a study. The headline does not say how large the study was or whether it was prospective (Bioengineer.org). - RIVANNA secured FDA clearance for AI-powered bone visualization software (BioBuzz). - A proof-of-concept study found that AI can learn to read equine emergency ultrasound windows. This is an early-stage result in animals (Bioengineer.org). - A piece on AI in radiology describes powerful tools alongside persistent blind spots (Bioengineer.org). - Meta will fund radiology AI research at Ohio State (Radiology Business).

Clinical decision support

Device approval and regulation

- RIVANNA's AI-powered bone visualization software received FDA clearance (BioBuzz). - Frontier Medicines' FMC-242 received FDA clearance to begin Phase 1/2 (Dealroom). - Modern Healthcare News examines how FDA generative AI device oversight may impact providers (Modern Healthcare News). - FDA and CMS are scrambling to avoid a regulatory logjam as more states look to test AI in clinical settings (STAT). - A California law adds guardrails on AI use in clinical care (Hunton Andrews Kurth LLP). - The Petrie-Flom Center discusses the disability gap in healthcare AI, from bias to inclusive co-design, testing, deployment and governance (Petrie-Flom Center). - CASRAI covers AI model governance in pharmacovigilance (PV) under E2B(R3) and FDA requirements (CASRAI).

Safety, errors and bias

- A researcher says "black box" medical AI can deepen health disparities (Association of Health Care Journalists). - Europe adopted a new AI healthcare roadmap (EMJ). - An MP is pushing for regulation of AI in healthcare and medical education (The Times of India). - Korea's medical AI is advancing, but clinical adoption remains slow (The Korea Times). - Global Brands Magazine ran a promotional-style piece on a "bold breakthrough" in medical AI. The headline gives no details (Global Brands Magazine). 【Research findings (major journals)】 - Medscape reports that AI chatbots may trigger delusions and fuel psychosis, citing what it calls the first systematic evidence (Medscape). - An NHS non-executive director (NED) warns that clinicians could be held responsible for AI errors (Digital Health). - Digital Health Wire covers medical superintelligence, an Anthropic IPO, and 2027 predictions (Digital Health Wire). - OpenEvidence partnered with ASAM to integrate addiction treatment guidelines into its AI platform (Digital Health News). - A paper examines generative AI as a hybrid threat multiplier in Mali's conflict. It is not a medical topic (accord.org.za).

Developments in Japan

- Japan's Ministry of Health, Labour and Welfare introduced retrieval-augmented generation (RAG) generative AI for freedom-of-information administration, and paper applications are converted to text with AI-OCR (IT Leaders). - A "next-generation remote image diagnosis" system with generative AI is described as supporting both management and patient services at small and mid-sized medical institutions (Niconico News). - South Korea and ASEAN are strengthening cooperation on AI in health care. This is a Korea-led item, not a Japanese one (Korea.net). - Two other items in this section's feed are not about medicine: a diagnostic tool for municipal websites (Infoseek) and a horse-racing forecast AI (SPAIA Keiba).

Statements by key figures

No notable developments.